Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma

Por Wader, K F, Fagerli, U M, Holt, R U, Stordal, B, Børset, M, Sundan, A, Waage, A
Publicado em 2008

Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin

Por Olsen, O E, Wader, K F, Misund, K, Våtsveen, T K, Rø, T B, Mylin, A K, Turesson, I, Størdal, B F, Moen, S H, Standal, T, Waage, A, Sundan, A, Holien, T
Publicado em 2014

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis

Por Rustad, E H, Dai, H Y, Hov, H, Coward, E, Beisvag, V, Myklebost, O, Hovig, E, Nakken, S, Vodák, D, Meza-Zepeda, L A, Sandvik, A K, Wader, K F, Misund, K, Sundan, A, Aarset, H, Waage, A
Publicado no Blood Cancer J (2015)